NasdaqCM - Nasdaq Real Time Price ? USD Exact Sciences Corporation (EXAS) Follow Compare 49.33 -1.60 (-3.14%) At close: November 15 at 4:00 PM EST 49.33 0.00 (0.00%) After hours: November 15 at 7:51 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock Those following along with Exact Sciences Corporation ( NASDAQ:EXAS ) will no doubt be intrigued by the recent purchase... Simply Wall St. ? yesterday EXAS -3.14% Exact Sciences showcases early cancer detection test data at AACR meeting New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung cancer. Clinical Trials Arena ? 2 days ago EXAS -3.14% Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy MADISON, Wis., November 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening Business Wire ? 4 days ago EXAS -3.14% Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund returned 9.15% while the benchmark, the Russell 2500 Growth Index, returned 6.99%. A strong market rally occurred throughout the quarter, and the Columbia Acorn Fund beat its benchmark […] Insider Monkey ? 6 days ago EXAS -3.14% Exact Sciences’ forecast cut shocks analysts The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday. MedTech Dive ? 9 days ago EXAS -3.14% Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield. Investor's Business Daily ? 10 days ago GH -3.64% EXAS -3.14% Exact Sciences Third Quarter 2024 Earnings: Misses Expectations Exact Sciences ( NASDAQ:EXAS ) Third Quarter 2024 Results Key Financial Results Revenue: US$708.7m (up 13% from 3Q... Simply Wall St. ? 10 days ago EXAS -3.14% Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken? Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. Investor's Business Daily ? 11 days ago EXAS -3.14% Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook. Investopedia ? 11 days ago EXAS -3.14% Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point On Tuesday, Exact Sciences Corp. (NASDAQ:EXAS) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20. The reported quarterly sales of $708.66 million missed the consensus estimate of $717.66 million. Screening revenue was $545 million, an increase of 15%, and Precision Oncology’s revenue was $164 million, an increase of 5% on a reported and core revenue basis. Also Read: FDA Clears Exact Sciences’ Next-Generation Col Benzinga ? 11 days ago EXAS -3.14% Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion. Zacks ? 11 days ago EXAS -3.14% DGX BSX Q3 2024 Exact Sciences Corp Earnings Call Q3 2024 Exact Sciences Corp Earnings Call Thomson Reuters StreetEvents ? 11 days ago EXAS -3.14% Exact Sciences Corp (EXAS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... Exact Sciences Corp (EXAS) reports a 13% revenue increase and record free cash flow, while navigating disruptions and strategic adjustments. GuruFocus.com ? 11 days ago EXAS -3.14% Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight Insightful Analysis of Exact Sciences Corp's Financial Health and Strategic Position GuruFocus.com ? 11 days ago EXAS -3.14% Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. Investor's Business Daily ? 11 days ago EXAS -3.14% Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript EXAS earnings call for the period ending September 30, 2024. Motley Fool ? 12 days ago EXAS -3.14% Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates Exact Sciences (EXAS) delivered earnings and revenue surprises of -5% and 1.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 12 days ago EXAS -3.14% Exact Sciences: Q3 Earnings Snapshot EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 21 cents. The results missed Wall Street expectations. Associated Press Finance ? 12 days ago EXAS -3.14% Exact Sciences Announces Third-Quarter 2024 Results MADISON, Wis., November 05, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023. Business Wire ? 12 days ago EXAS -3.14% High Growth Tech Stocks to Watch in November 2024 Over the last 7 days, the United States market has dropped 1.9%, yet it remains up by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these promising earnings projections. Simply Wall St. ? 12 days ago APLS IOVA EXAS -3.14% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return EXAS S&P 500 YTD -33.32% +23.08% 1-Year -22.27% +30.58% 3-Year -46.21% +25.36%
